ShareValue scores for LAVI.AT: Valuation 19, Quality 42, Growth 42, Health 43.

LAVI.AT
ATHEX

Lavipharm S.A

€1.57(-2.60%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-8% to 9%
Valuation
19
Overvalued
Price vs Value
Quality
42
Moderate
Business Strength
Growth
42
Moderate
Revenue & Earnings
Health
43
Moderate
Financial Stability
Momentum
80
Bullish
Price Trend

Company Details

About

Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs, such as antiseptics, anagelsics, and anti-lice treatment products. It also provides a range of skincare products focused on health. The company was founded in 1911 and is based in Paiania, Greece.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026